<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35254219</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2222-1751</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Emerging microbes &amp; infections</Title>
          <ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study.</ArticleTitle>
        <Pagination>
          <StartPage>885</StartPage>
          <EndPage>893</EndPage>
          <MedlinePgn>885-893</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2022.2050952</ELocationID>
        <Abstract>
          <AbstractText>Accruing evidence suggests an increased risk of myocarditis in adolescents from messenger RNA COVID-19 vaccines. However, other potential adverse events remain under-researched. We conducted a retrospective cohort study of adolescents aged 12-18 with a territory-wide electronic healthcare database of the Hong Kong population linked with population-based vaccination records and supplemented with age- and sex-specific population numbers. Two age- and sex-matched retrospective cohorts were formed to observe 28 days following the first and second doses of BNT162b2 and estimate the age- and sex-adjusted incidence rate ratios between the vaccinated and unvaccinated. Thirty AESIs adapted from the World Health Organization's Global Advisory Committee on Vaccine Safety were examined. Eventually, the first-dose cohort comprised 274,881 adolescents (50.25% received the first dose) and the second-dose cohort 237,964 (50.29% received the second dose). Ninety-four (34.2 per 100,000 persons) adolescents in the first-dose cohort and 130 (54.6 per 100,000 persons) in the second-dose cohort experienced ≥1 AESIs. There were no statistically significant differences in the risk of any AESI associated with BNT162b2 except myocarditis [first-dose cohort: incidence rate ratio (IRR) = 9.15, 95% confidence interval (CI) 1.14-73.16; second-dose cohort: IRR = 29.61, 95% CI 4.04-217.07] and sleeping disturbances/disorders after the second dose (IRR = 2.06, 95% CI 1.01-4.24). Sensitivity analysis showed that, with myocarditis excluded as AESIs, no significantly elevated risk of AESIs as a composite outcome associated with vaccination was observed (<i>P </i>= 0.195). To conclude, the overall absolute risk of AESIs was low with no evidence of an increased risk of AESIs except myocarditis and sleeping disturbances/disorders.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Francisco Tsz Tsun</ForeName>
            <Initials>FTT</Initials>
            <Identifier Source="ORCID">0000-0002-9121-1959</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chua</LastName>
            <ForeName>Gilbert T</ForeName>
            <Initials>GT</Initials>
            <Identifier Source="ORCID">0000-0003-0333-0059</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Edward Wai Wa</ForeName>
            <Initials>EWW</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwan</LastName>
            <ForeName>Mike Yat Wah</ForeName>
            <Initials>MYW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Tiantian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qin</LastName>
            <ForeName>Xiwen</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chui</LastName>
            <ForeName>Celine Sze Ling</ForeName>
            <Initials>CSL</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xue</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-4836-7808</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Eric Yuk Fai</ForeName>
            <Initials>EYF</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Carlos King Ho</ForeName>
            <Initials>CKH</Initials>
            <Identifier Source="ORCID">0000-0002-6895-6071</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chan</LastName>
            <ForeName>Esther Wai Yin</ForeName>
            <Initials>EWY</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Ian Chi Kei</ForeName>
            <Initials>ICK</Initials>
            <Identifier Source="ORCID">0000-0001-8242-0014</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Laboratory of Data Discovery for Health (D4H), Hong Kong Science Park, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ip</LastName>
            <ForeName>Patrick</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-6797-6898</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong Special Administrative Region, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Emerg Microbes Infect</MedlineTA>
        <NlmUniqueID>101594885</NlmUniqueID>
        <ISSNLinking>2222-1751</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N38TVC63NU</RegistryNumber>
          <NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Chinese</Keyword>
        <Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="N">coronavirus</Keyword>
        <Keyword MajorTopicYN="N">immunization</Keyword>
        <Keyword MajorTopicYN="N">reactogenicity</Keyword>
      </KeywordList>
      <CoiStatement>FTTL has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council and has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, outside the submitted work. CSLC has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA, and Amgen; and personal fees from PrimeVigilance; outside the submitted work. EYFW has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, and the Hong Kong Research Grants Council, outside the submitted work. XL has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; research and educational grants from Janssen and Pfizer; internal funding from the University of Hong Kong; and consultancy fees from Merck Sharp &amp; Dohme, unrelated to this work. EWYC reports honorarium from Hospital Authority; and grants from Research Grants Council (RGC, Hong Kong), Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Wellcome Trust, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, and Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region, outside the submitted work. PI has received funding from the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, and Hong Kong Jockey Club Charities Trust. ICKW receives research funding outside the submitted work from Amgen, Bristol-Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, National Institute for Health Research in England, European Commission, and the National Health and Medical Research Council in Australia; has received speaker fees from Janssen and Medice in the previous 3 years; and is an independent non-executive director of Jacobson Medical in Hong Kong. All other authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>12</Hour>
          <Minute>16</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35254219</ArticleId>
        <ArticleId IdType="pmc">PMC8942549</ArticleId>
        <ArticleId IdType="doi">10.1080/22221751.2022.2050952</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Miller IF, Becker AD, Grenfell BT, et al. . 
Disease and healthcare burden of COVID-19 in the United States. Nat Med. 2020;26:1212–1217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32546823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shekerdemian LS, Mahmood NR, Wolfe KK, et al. . 
Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units. JAMA Pediatr. 2020;174:868–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7489842</ArticleId>
            <ArticleId IdType="pubmed">32392288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opel DJ, Diekema DS, Ross LF.. 
Should we mandate a COVID-19 vaccine for children?
JAMA Pediatr. 2021;175:125–126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32926083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization.  Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. Geneva; 2021. https://apps.who.int/iris/bitstream/handle/10665/341786/WHO-2019-nCoV-vaccines-SAGE-recommendation-BNT162b2-2021.2-eng.pdf?sequence=1&amp;isAllowed=y.</Citation>
        </Reference>
        <Reference>
          <Citation>Food &amp; Drug Administration . FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. Washington DC; 2021. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.</Citation>
        </Reference>
        <Reference>
          <Citation>Shay DK, Shimabukuro TT, DeStefano F.. 
Myocarditis occurring after immunization with mRNA-based COVID-19 vaccines. JAMA Cardiol. 2021. DOI:10.1001/jamacardio.2021.2821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamacardio.2021.2821</ArticleId>
            <ArticleId IdType="pubmed">34185047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mevorach D, Anis E, Cedar N, et al. . 
Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021. 23–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8531987</ArticleId>
            <ArticleId IdType="pubmed">34614328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barda N, Dagan N, Ben-Shlomo Y, et al. . 
Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med.
2021;385:1078–1090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8427535</ArticleId>
            <ArticleId IdType="pubmed">34432976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt B, Kamat I, Hotez PJ.. 
Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8340726</ArticleId>
            <ArticleId IdType="pubmed">34281357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patone M, Mei XW, Handunnetthi L, et al. . 
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2021. DOI:10.1038/s41591-021-01630-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-021-01630-0</ArticleId>
            <ArticleId IdType="pmc">PMC8863574</ArticleId>
            <ArticleId IdType="pubmed">34907393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witberg G, Barda N, Hoss S, et al. . 
Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021. DOI:10.1056/NEJMoa2110737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2110737</ArticleId>
            <ArticleId IdType="pmc">PMC8531986</ArticleId>
            <ArticleId IdType="pubmed">34614329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hause AM, Gee J, Baggs J, et al. . 
COVID-19 vaccine safety in adolescents aged 12-17 years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1053–1058.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8367318</ArticleId>
            <ArticleId IdType="pubmed">34351881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husby A, Hansen JV, Fosbøl E, et al. . 
SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e068665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8683843</ArticleId>
            <ArticleId IdType="pubmed">34916207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Centre for Health Protection . Hong Kong vaccination dashboard; 2021. [cited 2021 Aug 27]. https://www.covidvaccine.gov.hk/en/dashboard/totalFirstDose.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization . WHO coronavirus (COVID-19) dashboard; 2021. [cited 2021 Oct 3]. https://covid19.who.int/.</Citation>
        </Reference>
        <Reference>
          <Citation>Wan EYF, Chui CSL, Lai FTT, et al. . 
Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis. 2021. DOI:10.1016/S1473-3099(21)00451-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(21)00451-5</ArticleId>
            <ArticleId IdType="pmc">PMC8367195</ArticleId>
            <ArticleId IdType="pubmed">34411532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Tong X, Yeung WWY, et al. . 
Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021. DOI:10.1136/annrheumdis-2021-221571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2021-221571</ArticleId>
            <ArticleId IdType="pmc">PMC8550868</ArticleId>
            <ArticleId IdType="pubmed">34686479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chua GT, Kwan MYW, Chui CSL, et al. . 
Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents following comirnaty vaccination. Clin Infect Dis. 2021. DOI:10.1093/cid/ciab989.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciab989</ArticleId>
            <ArticleId IdType="pmc">PMC8767823</ArticleId>
            <ArticleId IdType="pubmed">34849657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai FTT, Li X, Peng K, et al. . 
Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine. Ann Intern Med. 2022. DOI:10.7326/M21-3700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/M21-3700</ArticleId>
            <ArticleId IdType="pmc">PMC8814917</ArticleId>
            <ArticleId IdType="pubmed">35073155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai FTT, Huang L, Chui CSL, et al. . 
Multimorbidity and adverse events of special interest associated with Covid-19 vaccines in Hong Kong. Nat Commun. 2022;13:411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8776841</ArticleId>
            <ArticleId IdType="pubmed">35058463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Tong X, Wong ICK, et al. . 
Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut. 2022. DOI:10.1136/gutjnl-2021-326860.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/gutjnl-2021-326860</ArticleId>
            <ArticleId IdType="pubmed">35135842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sing C-W, Tang CTL, Chui CSL, et al. . 
COVID-19 vaccines and risks of hematological abnormalities: nested case-control and self-controlled case series study. Am J Hematol. 2022. DOI:10.1002/ajh.26478.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.26478</ArticleId>
            <ArticleId IdType="pubmed">35080247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong X, Wong CKH, Au ICH, et al. . 
Safety of inactivated and mRNA COVID-19 vaccination among patients treated for hypothyroidism: a population-based cohort study. Thyroid. 2022. DOI:10.1089/thy.2021.0684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2021.0684</ArticleId>
            <ArticleId IdType="pubmed">35216517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan EYF, Chui CSL, Wang Y, et al. . 
Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Reg Heal - West Pacific. 2022;21:100393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8808060</ArticleId>
            <ArticleId IdType="pubmed">35128500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Census and Statistics Department . Population estimates; 2021. [cited 2021 Nov 9]. https://www.censtatd.gov.hk/en/scode150.html.</Citation>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Background paper on Covid-19 disease and vaccines: prepared by the Strategic Advisory Group of Experts (SAGE) on immunization working group on COVID-19 vaccines, 22 December 2020. World Health Organization; 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Hong Kong Government . COVID-19 Vaccination Programme; 2021. [cited 2021 Aug 6]. 10.1001/jamapediatrics.2022.0101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapediatrics.2022.0101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gargano JW, Wallace M, Hadler SC, et al. . 
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8312754</ArticleId>
            <ArticleId IdType="pubmed">34237049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenblum HG, Hadler SC, Moulia D, et al. . 
Use of COVID-19 vaccines after reports of adverse events among adult recipients of Janssen (Johnson &amp; Johnson) and mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 20. MMWR Morb Mortal Wkly Rep. 2021;70:1094–1099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8360272</ArticleId>
            <ArticleId IdType="pubmed">34383735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perez Y, Levy ER, Joshi AY, et al. . 
Myocarditis Following COVID-19 mRNA vaccine: a case series and incidence rate determination. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2021. DOI:10.1093/cid/ciab926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciab926</ArticleId>
            <ArticleId IdType="pmc">PMC8767838</ArticleId>
            <ArticleId IdType="pubmed">34734240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz GA, Parsons GT, Gering SK, et al. . 
Myocarditis and Pericarditis After Vaccination for COVID-19. JAMA. 2021;326:1210–1212.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8340007</ArticleId>
            <ArticleId IdType="pubmed">34347001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li C, Chen Y, Zhao Y, et al. . 
Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model. Clin Infect Dis. 2021. DOI:10.1093/cid/ciab707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciab707</ArticleId>
            <ArticleId IdType="pmc">PMC8436386</ArticleId>
            <ArticleId IdType="pubmed">34406358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkanen TO, Alakuijala APE, Dauvilliers YA, et al. . 
Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev. 2018;38:177–186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28847694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hippisley-Cox J, Patone M, Mei XW, et al. . 
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8388189</ArticleId>
            <ArticleId IdType="pubmed">34446426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White RH, Keenan CR.. 
Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123:S11-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19303496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung GM, Tin KYK, O’Donnell O.. 
Redistribution or horizontal equity in Hong Kong’s mixed public–private health system: a policy conundrum. Health Econ. 2009;18:37–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18264997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong AYS, Root A, Douglas IJ, et al. . 
Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ. 2016;352. DOI:10.1136/bmj.h6926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.h6926</ArticleId>
            <ArticleId IdType="pubmed">26768836</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
